Hepatitis C Knowledge Assessment and Counseling within the Context of Substance Abuse treatment

Addictive Disorders and their Treatment

Volumn 3, Issue 1, 2004, Pages 18-26

  Evans, Mark ^a   Stotts, Angela L ^b,c   Graham, Susan ^a   Schmitz, Joy ^b   Grabowski, John ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UTMSI   (United States)

Author keywords

Counseling; Hepatitis C; Knowledge

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM;

EID: 1542744873     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132576-200403000-00003     Document Type: Article

References (63)

1. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med. 1999;107:79S-84S.
2. Paredes A, Zweben JE. The Hepatitis C epidemic, shall we remain silent? J Addict Dis. 2001;20:1-7.
3. Kirchner JT. Hepatitis C: who should we be treating? Am Fam Physician. 1999;59:273-274.
4. Thomas DL, Astemborski J, Rai RM, et al. The natural history of Hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.
5. Friedrich MJ. Third millennium challenge: Hepatitis C. JAMA. 1999;282:221-222.
6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of Hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
7. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30-S34.
8. Leigh JP, Bowlus CL, Leistikow BN, et al. Costs of Hepatitis C. Arch Intern Med. 2001;161:2231-2237.
9. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future Hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.
10. Gordon FD. Cost-effectiveness of screening patients for Hepatitis C. Am J Med. 1999;107:36S-40S.
11. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol. 1999;31(Suppl 1):88-91.
12. Delage G, Infante-Rivard C, Chiavetta JA, et al. Risk factors for acquisition of Hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology. 1999;116:893-899.
13. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the Hepatitis C, Hepatitis B human immunodeficiency, and human t-lymphotropic viruses. Am J Public Health. 1996;86:655-661.
14. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000;67:423-428.
15. Des Jarlais DC, Schuchat A. Hepatitis C among drug users: deja vu all over again? Am J Public Health. 2001;91:21-22.
16. Kenny-Walsh E. The natural history of Hepatitis C virus infection. Clin Liver Dis. 2001;5:969-977.
17. Aitken CK, Kerger M, Crofts N. Peer-delivered Hepatitis C testing and counseling: a means of improving the health of injecting drug users. Drug Alcohol Rev. 2002;21:33-37.
18. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61:211-215.
19. Smyth BP, McMahon J, O'Conner JJ, et al. Knowledge regarding Hepatitis C among injecting drug users. Drugs: education, Prevention and Policy. 1999;6:257-264.
20. Dhopesh VP, Taylor KR, Burke WM. Survey of Hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703-707.
21. Tortu S, Neaigus A, McMahon J, et al. Hepatitis C among noninjecting drug users: a report. Subst Use Misuse. 2001;36:523-534.
22. Rosenblum A, Nuttbrock L, McQuistion HL, et al. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis. 2001;20:15-25.
23. Alter MJ. Prevention of spread of Hepatitis C. Hepatology. 2002;36:S93-S98.
24. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. 2001;44:159-182.
25. Williams I. Epidemiology of Hepatitis C in the United States. Am J Med. 1999;107:2S-9S.
26. Giuliani M, Caprilli F, Gentili G, et al. Incidence and determinants of Hepatitis C virus infection among individuals at risk of sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program. Sex Transm Dis. 1997;24:533-537.
27. Tengan FM, Eluf-Neto J, Cavalheiro NP, et al. Sexual transmission of Hepatitis C virus. Rev Inst Med Trop Sao Paulo. 2001;43:133-137.
28. Thomas DL. Hepatitis C. Epidemiologic quandaries. Clin Liver Dis. 2001;5:955-968.
29. Thomas DL. Hepatitis C epidemiology. Curr Top Microbiol Immunol. 2000;242:25-41.
30. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex Transm Inf. 1998;74:399-404.
31. Wejstål R. Sexual transmission of Hepatitis C virus. J Hepatol. 1999;31(Suppl 1):92-95.
32. Pradat P, Trâepo C. HCV: epidemiology, modes of transmission and prevention of spread. Best Pract Res Clin Gastroenterol. 2000;14:201-210.
33. Neaigus A, Miller M, Friedman SR, et al. Sexual transmission risk among noninjecting heroin users infected with human immunodeficiency virus or Hepatitis C virus. J Infect Dis. 2001;184:359-363.
34. Cohen J. The scientific challenge of Hepatitis C. Science. 1999;285:26-30.
35. Delwaide J, Bourgeois N, Colle I, et al. Risk factors for Hepatitis C: past, present and future. Acta Gastroenterol Belg. 2002;65:87-89.
36. Daikos GL, Lai S, Fischl MA. Hepatitis C virus infection in a sexually active inner city population. The potential for heterosexual transmission. Infection. 1994;22:72-76.
37. Hershow RC, Kalish LA, Sha B, et al. Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Sex Transm Dis. 1998;25:527-532.
38. Centers for Disease Control and Prevention. A Comprehensive Strategy for the Prevention and Control of Hepatitis C Virus Infection and Its Consequences. Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention; 2001:1-19.
39. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep. 2002;51:1-78.
40. Feldman JG, Minkoff H, Landesman S, et al. Heterosexual transmission of Hepatitis C, Hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis. 2000;27:338-342.
41. Kao JH, Hwang YT, Chen PJ, et al. Transmission of Hepatitis C virus between spouses: the important role of exposure duration. Am J Gastroenterol. 1996;91:2087-2090.
42. Gyarmathy VA, Neaigus A, Miller M, et al. Risk correlates of prevalent HIV, Hepatitis B virus, and Hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr. 2002;30:448-456.
43. Stein GL, Fleischman AR. Addiction treatment: promoting a medical approach to substance use. J Urban Health. 1998;75:558-583.
44. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR Recomm Rep. 1998;47:1-111.
45. Edlin BR. Prevention and treatment of Hepatitis C in injection drug users. Hepatology. 2002;36: S210-S219.
46. van Hattum J. Health strategy on HCV in The Netherlands. Acta Gastroenterol Belg. 2002;65:115-117.
47. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50:1-57.
48. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep. 2001;50:63-85.
49. Moyer LA, Mast EE, Alter MJ, et al. Hepatitis C: Part II. Prevention counseling and medical evaluation. Am Fam Physician. 1999;59:349-354, 357.
50. Grella CE, Etheridge RM, Joshi V, et al. Delivery of HIV risk-reduction services in drug treatment programs. J Subst Abuse Treat. 2000;19:229-237.
51. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA. 1998;280:1161-1167.
52. Gunn RA, Murray PJ, Ackers ML, et al. Screening for chronic Hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis. 2001;28:166-170.
53. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17:539-544.
54. Strauss SM, Falkin GP, Vassilev Z, et al. A nationwide survey of Hepatitis C services provided by drug treatment programs. J Subst Abuse Treat. 2002;22:55-62.
55. Elk R, Grabowski J, Rhoades H, et al. A substance-abuse research-treatment clinic: effective procedures and systems. J Subst Abuse Treat. 1993;10:459-471.
56. Centers for Disease Control and Prevention. Technical guidance on HIV counseling. MMWR. 1993;42:8-17.
57. USDHHS. HIV Counseling, Testing, and Referral Standards and Guidelines. Atlanta, GA: Public Health Service, Centers for Disease Control and Prevention; 1994.
58. Heimer R, Clair S, Grau LE, et al. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three U.S. cities. Addiction. 2002;97:1277-1287.
59. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9:199-213.
60. Mansson AS, Moestrup T, Nordenfelt E, et al. Continued transmission of Hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000;32:253-258.
61. van Beek I, Dwyer R, Dore GJ, et al. Infection with HIV and Hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317:433-437.
62. Centers for Disease Control and Prevention. Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19): 1-39.
63. Pollack HA. Cost-effectiveness of harm reduction in preventing Hepatitis among injection drug users. Med Decis Making. 2001;21:357-367.